Literature DB >> 8509271

Dopamine D2 receptor imaging with SPECT using IBZM in 16 patients with Parkinson disease.

D Giobbe1, G C Castellano, V Podio.   

Abstract

The striatal D2 receptor was investigated for variability of behavior in 16 patients with Parkinson disease by means of SPECT using 123I-IBZM, a recently synthesized radioligand with high affinity and specificity for this type of receptor. All the patients underwent routine laboratory tests, EEG and cranial CT scanning as well as SPECT. To ensure accurate clinical assessment we used the Hoehn and Yahr, and Webster scales, NUDS and Mini Mental State examination. Our preliminary data indicate: increased uptake by the striatal dopamine receptor in untreated patients with early PD compared with controls (striatum/cerebellum ratio of 1.77 +/- 0.12 vs 1.59 +/- 0.13); a slight but significant lowering of D2 receptor binding when L-Dopa is started (1.49 +/- 0.09); low D2 uptake values in the more severely affected patients; absence of asymmetries in hemiparkinsonism.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8509271     DOI: 10.1007/BF02335751

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  9 in total

Review 1.  Dopamine receptors and transporters in Parkinson's disease and schizophrenia.

Authors:  P Seeman; H B Niznik
Journal:  FASEB J       Date:  1990-07       Impact factor: 5.191

2.  Dopamine receptor properties in Parkinson's disease and Huntington's chorea evaluated by positron emission tomography using 11C-N-methyl-spiperone.

Authors:  J Hägglund; S M Aquilonius; S A Eckernäs; P Hartvig; H Lundquist; P Gullberg; B Långström
Journal:  Acta Neurol Scand       Date:  1987-02       Impact factor: 3.209

3.  Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases.

Authors:  P Seeman; N H Bzowej; H C Guan; C Bergeron; G P Reynolds; E D Bird; P Riederer; K Jellinger; W W Tourtellotte
Journal:  Neuropsychopharmacology       Date:  1987-12       Impact factor: 7.853

4.  Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders.

Authors:  T Brücke; I Podreka; P Angelberger; S Wenger; A Topitz; B Küfferle; C Müller; L Deecke
Journal:  J Cereb Blood Flow Metab       Date:  1991-03       Impact factor: 6.200

5.  In vivo characterisation of 3-iodo-6-methoxybenzamide 123I in humans.

Authors:  D C Costa; N P Verhoeff; I D Cullum; P J Ell; G M Syed; J Barrett; E Palazidou; B Toone; E Van Royen; M Bobeldijk
Journal:  Eur J Nucl Med       Date:  1990

6.  Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease.

Authors:  U K Rinne; A Laihinen; J O Rinne; K Någren; J Bergman; U Ruotsalainen
Journal:  Mov Disord       Date:  1990       Impact factor: 10.338

7.  Dopamine uptake sites and dopamine receptors in Parkinson's disease and schizophrenia.

Authors:  R K Pearce; P Seeman; K Jellinger; W W Tourtellotte
Journal:  Eur Neurol       Date:  1990       Impact factor: 1.710

8.  PET studies of dopamine receptor distribution using [18F]fluoroethylspiperone: findings in disorders related to the dopaminergic system.

Authors:  K Wienhard; H H Coenen; G Pawlik; J Rudolf; P Laufer; S Jovkar; G Stöcklin; W D Heiss
Journal:  J Neural Transm Gen Sect       Date:  1990

9.  Transplantation in Parkinson's disease: two cases of adrenal medullary grafts to the putamen.

Authors:  O Lindvall; E O Backlund; L Farde; G Sedvall; R Freedman; B Hoffer; A Nobin; A Seiger; L Olson
Journal:  Ann Neurol       Date:  1987-10       Impact factor: 10.422

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.